POZEN Inc. POZN, a pharmaceutical company committed to transforming
medicine that transforms lives, today announced the submission of a New Drug
Application (NDA) to the U.S. Food and Drug Administration (FDA) for the
marketing approval of PA32540/PA8140. Both products are a coordinated-delivery
tablet combining immediate-release omeprazole (40 mg), a proton pump inhibitor
(PPI), layered around a pH-sensitive coating of an aspirin core. Pending
regulatory approval, an indication is sought for the use of PA tablets for the
secondary prevention of cardiovascular disease in patients at risk for
aspirin-induced ulcers.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in